Objective. To determine the role of Jinhuang Powder to prevent adverse effects of subcutaneous injection of enoxaparin sodium. Methods. The clinical data of 97 patients with cervical cancer who were treated with subcutaneous injection of enoxaparin through the lower margin of the deltoid muscle of the upper arm in Zhejiang Tumor Hospital from August 2020 to August 2021 were retrospectively analyzed. All patients were divided into the control group (n = 39) and the research group (n = 58) according to the different use time periods of Jinhuang Powder. The research group was treated with Jinhuang Powder and enoxaparin sodium at the same time. The control group started to use Jinhuang Powder after the adverse reactions occurred. The induration, subcutaneous bleeding events, and pain were statistically analyzed. Results. The incidence of induration (3.4% vs 15.4%, ) and subcutaneous hemorrhage (37.9% vs 76.9%, ) in the research group was significantly lower than that in the control group. The pain in the research group was lighter than that in the control group (grade 0–4 pain: 70% vs 28.2%, 19% vs 30.8%, 8.6% vs 23.1%, 1.7% vs 12.8%, 1.7% vs 5.1%, ). Conclusion. Preventive use of Jinhuang Powder can significantly reduce the incidence of subcutaneous induration and subcutaneous bleeding and can effectively alleviate the local pain of injection. It is worthy of further study to clarify its role and mechanism.

中文翻译：

---

金黄散预防依诺肝素钠皮下注射不良反应的作用

客观的。确定金黄散预防依诺肝素钠皮下注射不良反应的作用。方法。回顾性分析2020年8月至2021年8月在浙江省肿瘤医院上臂三角肌下缘皮下注射依诺肝素治疗的97例宫颈癌患者的临床资料。将所有患者分为对照组（n  =39）和研究组（n = 58) 根据金黄散的不同使用时间段。研究组同时给予金黄散和依诺肝素钠治疗。对照组出现不良反应后开始使用金黄散。对硬结、皮下出血事件和疼痛进行统计分析。结果。硬结的发生率（3.4% vs 15.4%，)和皮下出血 (37.9% vs 76.9%,)研究组显着低于对照组。研究组的疼痛比对照组轻（0-4级疼痛：70% vs 28.2%、19% vs 30.8%、8.6% vs 23.1%、1.7% vs 12.8%、1.7% vs 5.1% ,）。 结论。预防性使用金黄散可显着降低皮下硬结和皮下出血的发生率，并能有效缓解注射局部疼痛。其作用和作用机制值得进一步研究。